NICE relents and okays Akcea’s rare disease drug Waylivra for NHS usePatients with the rare disease familial chylomicronemia syndrome (FCS) will be able to access treatment with Akcea’s Waylivra Share XNICE relents and okays Akcea’s rare disease drug Waylivra for NHS usehttps://pharmaphorum.com/news/nice-relents-and-okays-akceas-rare-disease-drug-waylivra-for-nhs-use/
Ionis deal delivers for GSK as HBV drug hits the mark in phase 2An antisense drug developed by GlaxoSmithKline has been shown to suppress the hepatitis B virus (HBV) in a Share XIonis deal delivers for GSK as HBV drug hits the mark in phase 2https://pharmaphorum.com/news/ionis-deal-delivers-for-gsk-as-hbv-drug-hits-the-mark-in-phase-2/
Roche takes on development of potential Huntington’s breakthroughIonis has completed its licensing agreement with Roche for IONIS-HTTRx, a drug which could be a breakthrough in Share XRoche takes on development of potential Huntington’s breakthroughhttps://pharmaphorum.com/news/roche-takes-development-potential-huntingtons-breakthrough/
